8-K: CD&R, McKesson to Acquire Option Care Health for $32.05/Share

Option Care Health has entered into a definitive agreement to be acquired by an investor group led by Clayton, Dubilier & Rice, LLC and McKesson Corporation for $32.05 per share.

Summary

• Option Care Health, Inc. has agreed to be acquired by an investor group comprising affiliates of Clayton, Dubilier & Rice, LLC (CD&R) and McKesson Corporation.
• The transaction values Option Care Health at approximately $5.8 billion, with an enterprise value of $5.8 billion.
• Shareholders will receive $32.05 in cash per share, representing a premium of approximately 37% over the closing share price on October 5, 2026.
• CD&R will hold a majority ownership interest (approximately 51%), and McKesson will hold a minority interest (approximately 49%).
• Option Care Health will continue to operate as a separate company led by its current management team.
• The transaction is expected to close in the first half of calendar year 2027, subject to customary closing conditions, including stockholder approval and regulatory approvals.
• Following the closing, Option Care Health will cease to be a publicly listed company on the Nasdaq Stock Market.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, indicating a significant premium for shareholders and strategic backing from established players.

Positives

• Shareholders will receive a significant cash premium of approximately 37% over the last trading day's closing price.
• The acquisition provides immediate cash value for Option Care Health stockholders.
• The transaction is supported by the unanimous recommendation of Option Care Health's Board of Directors.
• The backing of experienced healthcare investors like CD&R and McKesson is expected to support Option Care Health's growth and strategic initiatives.
• McKesson's involvement aligns with its strategy to expand access to innovative therapies and community-based care.
• Option Care Health will continue to operate independently with its existing management team, ensuring continuity.

Negatives

• Option Care Health will no longer be a publicly traded company, limiting future public market access for investors.
• The withdrawal of Option Care Health's third-quarter 2026 financial guidance and cancellation of its earnings conference call may create short-term uncertainty.
• The transaction is subject to customary closing conditions, including stockholder approval and regulatory approvals, which could delay or prevent completion.

Risks

• The inability to complete the proposed transaction due to failure to obtain stockholder approval or satisfy other closing conditions.
• Regulatory approvals, including those related to healthcare regulations and antitrust laws, may be delayed or not obtained.
• Potential litigation related to the proposed transaction could arise.
• Restrictions on the Company's business operations during the pendency of the transaction may impact its ability to pursue opportunities.
• Announcements related to the transaction could have adverse effects on the market price of the Company's common stock, credit ratings, or operating results.
• The transaction and its announcement could adversely affect the Company's ability to retain and hire key personnel, retain customers, and maintain relationships with business partners.
• Management's time and attention may be diverted from ordinary course business operations to the completion of the transaction.

Future Outlook

The filing indicates that Option Care Health will continue to operate as a separate company led by its management team, with the support of CD&R and McKesson to invest strategically and accelerate technology deployment to improve clinical outcomes and reduce the total cost of care. McKesson views the investment as an opportunity to expand access and affordability to innovative therapies across the care continuum.

Management Comments

• "We are pleased to have entered into this agreement, which provides immediate cash value for our stockholders," said Harry Kraemer, Chairman of the Board of Option Care Health.
• "The Board of Directors completed an extensive assessment, involving thorough discussions with our advisors, and unanimously concluded this transaction maximizes value for our stockholders."
• "This transaction represents a great outcome for Option Care Health and our stockholders, and I want to thank our Board of Directors for their rigorous process and diligence," said John C. Rademacher, Chief Executive Officer of Option Care Health.
• "For more than 45 years, Option Care Health has helped transform the way infusion therapy is delivered, led by our team members unwavering commitment to providing extraordinary care to patients."
• "We will continue to enhance our platform and deepen our partnerships with hospitals and health systems, physicians, payers, and biopharma manufacturers."
• "We are thrilled to have the support of CD&R and McKesson, empowering us to continue investing strategically and accelerate the pace of our advanced technology deployment to improve clinical outcomes and reduce the total cost of care."
• "Both firms understand our business and the healthcare industry, and have proven track records of fostering growth for some of the largest and fastest-growing healthcare service businesses globally."
• "This investment represents an important opportunity that aligns with McKesson's long-term strategy to expand access and affordability to innovative therapies across the care continuum," said Brian Tyler, Chair and Chief Executive Officer of McKesson.

Industry Context

StockSavvy.ai notes that this acquisition reflects a broader trend of consolidation and strategic investment within the healthcare services sector, particularly in areas like home and alternate site infusion services. The involvement of private equity (CD&R) and a major healthcare distributor (McKesson) highlights the increasing focus on optimizing care delivery, leveraging technology, and expanding patient access to specialized therapies outside traditional hospital settings.

Comparison to Industry Standards

• The transaction price of $32.05 per share represents a 37% premium to Option Care Health's closing share price on October 5, 2026, which is a substantial premium compared to typical M&A premiums in the healthcare services sector.
• The total enterprise value of approximately $5.8 billion for a provider of home and alternate site infusion services indicates a significant valuation, potentially reflecting the strategic importance of this segment within the broader healthcare landscape.
• The involvement of both a private equity firm (CD&R) and a strategic corporate buyer (McKesson) is a common structure in large healthcare transactions, aiming to combine financial backing with operational expertise.

Legal Proceedings

• The filing mentions 'Transaction Litigation' as a potential risk, which refers to any legal proceedings commenced or threatened against a party or its affiliates in connection with the transactions.

Stakeholder Impact

• Shareholders: Will receive $32.05 per share in cash, representing a significant premium.
• Employees: Option Care Health will continue to operate with its current management team. Continuing employees will receive comparable salary, incentive opportunities, and substantially similar benefits for at least 12 months post-closing.
• Customers/Patients: Option Care Health will continue to operate as usual, with the same commitment to patients and providers. The backing of CD&R and McKesson is expected to enhance service delivery and technology deployment.
• Partners (Hospitals, Health Systems, Physicians, Payers, Biopharma Manufacturers): Option Care Health will continue to deepen partnerships, with potential for enhanced capabilities and strategic investment due to new ownership.

Next Steps

• Option Care Health stockholders must approve the merger agreement.
• Required regulatory approvals, including antitrust and healthcare regulatory filings, must be obtained.
• The transaction is expected to close in the first half of calendar year 2027.

Key Dates

Recommendation

The offer price of $32.05 per share represents a significant premium (37%) over the recent trading price, making it an attractive cash-out opportunity for existing shareholders. However, for investors who believe in Option Care Health's long-term growth potential, especially with the strategic backing of CD&R and McKesson, holding might be considered if there's a belief that the company's intrinsic value could exceed the offer price in the long run, though the certainty of cash is compelling. Given the all-cash nature and substantial premium, a 'hold' is appropriate for those considering not tendering immediately, while tendering is the most direct path to realizing the premium.

Keywords

Merger Agreement, Acquisition, Option Care Health, Clayton Dubilier & Rice, McKesson Corporation, Infusion Services, Home Infusion, Healthcare Services